

The Haemophilia Society
(A company limited by guarantee)
Financial statements
Year ended 31st March 2017

Charity registration number: 288260

Scottish charity registration number: SCO39732

Company registration number: 01763614

The Haemophilia Society

Financial statements

Year ended 31st March 2017

Contents

	Page
Charity reference and administrative details	1
Chair's statement	3 - 4
Trustees' annual report (including directors' report and strategic report)	5 - 17
Independent auditors' report	18
Statement of financial activities (including income and expenditure account)	19
Balance sheet	20
Statement of cash flows	21
Notes to the financial statements	22 - 33

The Haemophilia Society

Charity reference and administrative details

Year ended 31st March 2017

President Baroness Molly Meacher

Chief Executive Liz Carroll

Board of Trustees Barry Flynn – Chair
Lisa Bagley
Helen Campbell
Liz de Freitas
Kate Khair
Andrew Martin
Simon Mower
Jamie O'Hara
Collette Pigden
Eileen Ross
Barbara Scott
Clive Smith

Subcommittees

Resources & Audit Committee Simon Mower – Chair
Liz Carroll
Liz De Freitas
Barry Flynn

Nominations Committee Helen Campbell
Liz Carroll
Barry Flynn
Barbara Scott

Clinical Advisory Group Dr Rezan Abdul-Kadir
Dr Gary Benson
Dr Andrew Brewer
Susan Hook
Robert James
Dr Kate Khair
Dr Mike Laffan
Dr Mike Makris
Andrew Martin
Debra Pollard
Mark Simmons
David Stephenson

The Haemophilia Society

Charity reference and administrative details

Year ended 31st March 2017

Company Secretary	Liz Carroll
Bankers	The Co-operative Bank Plc Relationship Accountant Support Service Team PO Box 250 Skelmersdale WN6 6WT
Solicitors	Stone King LLP 13 Queen Square Bath BA1 2HJ
Auditors	Wilkins Kennedy LLP Bridge House London Bridge London SE1 9QR
Registered Office	Ground Floor Willcox House 140-148 Borough High Street London SE1 1LB
Company registration number	01763614
Charity registration number	288260
Scottish charity registration number	SCO39732

The Haemophilia Society

Trustees' annual report

Year ended 31st March 2017

Chair's Statement

It is with great pleasure that I reflect on a year of continuing achievement for The Haemophilia Society. Against a challenging backdrop of Brexit uncertainty and despite the inevitable bumps in the road that come with being a relatively small charity we made considerable progress in our mission to provide services to everyone affected by a bleeding disorder and to influence government policy and health practice on behalf of our community.

Undoubtedly the hiatus resulting from the departure of our previous Head of Fundraising contributed to the widening of our operating deficit this year, before the receipt of a very substantial legacy which serendipitously increased our unrestricted reserves. The experience served to heighten our awareness of how valuable legacies are to us, how reliant we remain on corporate giving, and how much we have still to do to increase our self-resilience by broadening and diversifying our sources of funding. I have been very encouraged by the way the team is tackling this issue and the impact this is already having.

Much more positively, however, we saw membership numbers increase this year, from 5,435 to 5,597, including 92 more female members, which to me is the fundamental indicator of the relevance and effectiveness of the work The Society is doing. The year has seen unprecedented levels of events and communications across all the key life stages, and feedback from members strongly indicates that their needs are being addressed. We have also continued to invest in website content, strengthened relationships with local groups and progressed the Youth Ambassador programme.

As well as our efforts to inform and support members in leading fulfilling lives, we have tried throughout the year to reflect your collective views in communicating with Government, the NHS and health care professionals, to ensure that a strong, concerted community voice is heard as loudly and effectively as possible where it needs to be. Whether or not it is listened to, by Government in particular, has been a continuing source of frustration for all of us. Recent developments may indicate a change in attitude on this front but we will keep applying pressure until a properly constituted Inquiry with appropriate powers and scope is underway. The Society will continue to advocate for a speedy and comprehensive settlement for everyone impacted by the contaminated blood disaster and access to the best possible treatment.

One of my most memorable experiences of the year was attending the World Federation of Haemophilia Congress in Orlando. My abiding impressions were of just how huge the global community is, how much still needs to be done to achieve the overriding goal of "treatment for all" (still today more than half the people with haemophilia in the world receive no treatment at all, and have short, curtailed lives, never mind those who have other bleeding disorders) and what a powerful voice we can be when we act together. It was also a heart-stopping moment when I realised that would be me on stage opening the 2018 Congress next May in Glasgow! I hope that many of you will be able to join us for what will be a hugely successful event with the bleeding disorder world's focus on the UK. Preparations have been underway for many months and our team are playing a vital role in many aspects of this work, and we are all looking forward to a successful Congress.


The Haemophilia Society

Trustees' annual report


Year ended 31st March 2017

Finally, I would like to thank Liz Carroll, our indefatigable CEO and her dedicated and hardworking team, for another year of relentless effort, aided and abetted by a huge number of people, paid and unpaid, who have contributed to the work of The Society; my fellow trustees, member volunteers and youth ambassadors, clinician advisors, MPs on the All Party Parliamentary Group, all those helping to plan the Glasgow Congress, those who have raised funds and those who have donated. All are contributors to the success we have enjoyed this year. The landscape remains challenging and uncertain, and funding will be a continuing challenge, but given what we have, I am confident that next year will be another good one.

Barry Flynn

A handwritten signature in black ink, consisting of a large, stylized 'B' followed by a horizontal line that ends in a small loop.

Chair of the Board of Trustees
The Haemophilia Society



The Haemophilia Society

Trustees' annual report

Year ended 31st March 2017

Trustees Report

The trustees present their report and the audited financial statements of the charity for the year ended 31st March 2017. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) *Accounting and Reporting by Charities* (FRS 102) in preparing the annual report and financial statements of the charity. The Trustees' Annual Report incorporates the Directors' Report and Strategic Report.

The financial statements have been prepared in accordance with the accounting policies set out in notes to the accounts and comply with the charity's governing document, the Charities Act 2011 and *Accounting and Reporting by Charities: Statement of Recommended Practice* applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland published on 16th July 2014.

Trustees of the charity

The directors of the charitable company are its trustees for the purposes of charity law. The trustees who have served during the year and since the year end were as follows:

Lisa Bagley
Helen Campbell
Liz de Freitas
Barry Flynn
Kate Khair
Andrew Martin
Simon Mower
Jamie O'Hara
Collette Pigden
Eileen Ross (from November 2016)
Barbara Scott
Clive Smith
Paul Teuten (to March 2017)

Our vision, mission and values

Our vision: Wellbeing for everyone with a bleeding disorder.

Our mission: For all those affected by bleeding disorders, we will provide information and services; build community and mutual support; influence government health and welfare policies, including advocating for those impacted by contaminated blood; and involve people in making decisions about their own care.

Our values: We relate everything we do to the needs of everyone affected by bleeding disorders; act with integrity, honesty and transparency; make the best use of our resources; and are inclusive and independent.

The Haemophilia Society

Trustees' annual report

Year ended 31st March 2017

Public benefit statement

The Haemophilia Society's services are available to everybody affected by inherited bleeding disorders in the UK. We have over 5,500 members; membership is open to all, with no charge, and services are open to members and non-members alike. We provide social, psychological, and practical support, complementing the care given by the NHS and bringing people together to reduce the isolation many of our community experience. We advocate to ensure levels of NHS service are maintained and improved, and encourage patients to become involved in decision making about their own treatment. We are recognised by the government as a key patients' representative promoting informed patient involvement in monitoring and developing services.

The trustees have paid due regard to the Charity Commission guidance on public benefit when reviewing the charity's objectives and activities.

Objectives and activities

Specific objectives and activities providing public benefit include:

Providing information, services and support on all aspects of inherited bleeding disorders, enabling people to live well and make informed decisions about their own treatment and care. Information is provided at service events, by phone and email, and through a website, very active Facebook pages, leaflets on specific aspects of bleeding disorders, a network of local groups, and publications.

Running day and residential events for different groups of people with bleeding disorders in order to provide social support and education.

Ensuring that the patients' viewpoint is heard in key NHS and Department of Health forums, for example on the Clinical Reference Group for Haemophilia.

Escalating issues of provision of care to the NHS government health teams.

Advocating for fair treatment and support for those impacted by the contamination of blood products supplied by the NHS in the 1970s and 1980s.

Commissioning research with the intention of benefiting those with bleeding disorders.

Fundraising regulation

We have done a lot of work this year to evaluate our policies, processes and procedures. We have adopted and signed up to the Fundraising Regulators 'Fundraising Promise' which summarises our commitment to individuals who support our work. The promise includes a commitment to make our supporters' experience as positive and rewarding as we can. We are committed to being honest and transparent about where our supporters' donations go and why we need funding. The safety of our supporters' data is very important to us.

We are determined to take all obligations very seriously and we will:

- never sell or share our supporters' data with any third party fundraising organisations;
- be both respectful and accountable to our supporters;
- continue to be sensitive when engaging with vulnerable people and our practices will reflect this; and
- continue to ensure our supporters feel valued and in control of their relationship with us.

The Haemophilia Society

Trustees' annual report

Year ended 31st March 2017

As reported to the Fundraising Regulator we had ZERO complaints during the previous time period around fundraising. We do not, and have not, engaged with any third party to fundraise on our behalf.

Strategic report

Introduction

We are the only UK-wide charity for everyone affected by an inherited bleeding disorder, a community which includes family members, healthcare professionals and other supporters. Since 1950 we have campaigned for better treatment, been a voice and a source of information and support, and have helped members to lead fulfilling lives and inspire others to do so.


Around 26,000 people in the UK have a diagnosis of an inherited bleeding disorder. Approaching 7,000 are males with haemophilia, but there are also around 2,000 females registered as carrying a defective gene who also often have low levels of factor VIII and have haemophilia. The largest proportion of people who have an inherited bleeding disorder have von Willebrand disease, but there are many rarer bleeding disorders that affect both men and women.



THE
HAEMOPHILIA
SOCIETY

est. 1950

Celebrating 67 yrs



5597 members

3% increase 16-17

51% women

49% men



newborn - 96

SERVICES 2016-17

We ran 14 x
member
events
engaging 264
members in
2016-17

3

Newly-diagnosed
weekends

1

Create Arts
weekend

1

Ageing
Conference

1

Sports Day

3

Youth
Weekends

1

Global Family
Picnic

1

HIV Info Day


1

Inhibitor
Conference

2

Workshops
for ageing/
inhibitors projects

FOR A FULLER LIST OF SERVICES VISIT www.haemophilia.org.uk



“

Being able to meet other families and sharing some experiences helped me to deal with certain feelings and experiences I hadn't dealt with before

”




The Haemophilia Society is the only UK-wide charity for all those affected by genetic bleeding disorders.

We help people to lead fulfilling lives make informed choices and to support and inspire others

Publications




3 new publications

Schools, VWD, Understanding haemophilia




3 in development

Rare disorders, Sex, Dental care



Advocacy & Campaigning



105 MPs


are members of the APPG supporting the campaign to call for justice over the #contaminatedblood scandal

14 mentions of The Haemophilia Society in parliament compared with 4 in the previous 2 years combined



??

!



In the 70s and 80s over 4500 people with bleeding disorders were infected by blood-borne viruses including HIV and hep C via treatment with contaminated blood products.

As a community, we raised our voices to say that this must not be ignored or forgotten, and the government must not cut funding for those affected.

Our #ContaminatedBlood campaign called for the government to:

- ✓ Answer why people in England stand to be worse off than they are and receive less support than those in Scotland
- ✓ Offer HIV and Hep C affected patients affected by the #ContaminatedBlood scandal the dignity they deserve
- ✓ Provide at least the same support as Scotland
- ✓ Deliver sustainability and security to the community, ensuring no one is worse off in a new scheme

Governance

Reduced costs



- Reviewed and renewed all policies
- Reduced costs on all contracts
- Trustee governance review and new risk assessment process. Safeguarding and Data Protection training and review



Safeguarding

Risk Assessment



Data protection



Communications



“

It is impossible to stress how invaluable the support is of this network even after the event, thanks to the power of social media. Knowing the faces behind the profile pics makes all the difference!

”

We launched a new e-newsletter with very positive results

44.9% OPEN RATE
8.7% CLICK RATE



Social media



3367 up 6%




2787 up 4%

139k Twitter impressions

360 Twitter clicks


In spring we launched a new website, which is continually evolving with new content, member stories and news updates, and has reduced ongoing costs



Fundraising

9 Key Events

100+ Fundraisers




London Marathon

Our top event was the London Marathon which in a total of £25,500 from 9 runners. One member alone raised nearly £8000!

“

Raising money by wading through cold wet mud still made us smile!

”



Things we are proud of

We are proud to be co-hosts and organisers of the WFH World Congress 2018 held in Glasgow



“ Reassuring to feel you share an experience with other people in a really lovely environment. But mostly exposure to the excellent guys living with haemophilia and showing us how in real life they manage, worth a million words ”



We held the 2nd Talking Red Week in June and it was great! Lots of people raised loads of funds and awareness

HQ

The Winter edition of HQ went out & was well-received

We launched a new website which was more cost-efficient


Things we can do better




Grow and diversify income, expand range and geography of fundraising events for more unrestricted funds



More regular and more consistent communication with our members



Increased reach, stronger advocacy for our members, more member-led campaigning.



Broader membership, better engagement

The Haemophilia Society

Trustees' annual report

Year ended 31st March 2017

Financial review

Income and expenditure overview

The results for this financial year continue to demonstrate the known challenges faced by The Society in respect of a volatile fundraising environment, whilst also highlighting the engagement of the community.

Overall we have generated a significant surplus for the year of £439,378 (before the impact of gains and losses on investments), which results in The Society being well capitalised and on a more secure financial footing than for a number of years.

However, this surplus was swelled by a material legacy of £675,000 which was gratefully received during the year. Excluding this legacy, our outcome for the year would have been a deficit of £(235,622). This was driven by lower than budgeted income, in respect of corporate income, individual giving and community fundraising which was in part caused by the unforeseen departure of our lead fundraiser during the year.

The Senior Management Team and Board of Trustees has proactively strengthened the fundraising team during the year and has actioned fundraising plans which are targeted to return The Society to a breakeven position over the next 24 months.

Income (including legacies) for FY17 was £1,176,886, as compared to £645,339 in FY16. This included corporate funding of £197,633 in FY17 (down from £317,684 in FY16, which included some one-off amounts) and a reduction in individual donations and community fundraising (combined) from £240,507 in FY16 to £198,484 in FY17.

Expenditure for FY17 increased by £84,012 to £737,508 from £653,496 in FY16. There are two core factors that explain this:

- Costs of raising funds decreased by £17,436 compared to FY16. This was driven in part by the unforeseen departure of our lead fundraiser during the year. We would expect this to be partly reversed in FY18; and
- Cost of charitable activities increased by £101,448 compared to FY16. This was driven by investment in the staff base to provide increased service levels in areas such as public policy and communication and an increasing focus on time spent on charitable activities

We very gratefully benefited from legacy income of £735,555 during the year (FY16: £36,140).

The Society retains a strong base of reserves and a solid financial position, which has further strengthened this year. The Board of Trustees continues to consider selective investment opportunities for the deployment of reserves into charitable activities where it is deemed that there could be significant benefit to the community from undertaking them. Balanced against this, we are also mindful of the recent volatility of fundraising and so we will continue to act prudently in this respect.

Fundraising and volunteers

The Society's members have participated in many fundraising activities this year and have made significant donations of £198,484. We have benefited from members participating in a wide range of events alongside individual giving, for all of which we are very grateful.

We are focused on continuing to support and promote any fundraising undertaken by our members and friends as a most important and valued source of unrestricted income and a way to highlight our services to the widest community.

The Haemophilia Society

Trustees' annual report

Year ended 31st March 2017

The charity also benefits from a number of volunteers involved in many aspects of our work including as trustees, as part of Local Groups, assisting at events and helping in the office. We very much appreciate the important contribution of all these volunteers to our work.

We are also grateful for the extensive pro-bono support from professionals The Society received during the year.

Trust income

We have reinvigorated our focus on applications for trust donations, and would expect this to be an area of gradual growth over the coming years. We have received income from trust applications of £7,740 this year (FY16: £5,350). Broadening our sources of income is an area in which we continue to focus.

Corporate income

Corporate income decreased from £317,684 in FY16 to £197,633 in FY17, which reflects a more normalised level of income following a strong year in FY16 which contained several one-off items. The total was however lower than we had budgeted, driven partly by later than expected receipt of amounts compared to prior years and partly by the departure of our lead fundraiser, meaning we were not able to get all our applications in within the required funding cycle. This remains a key area of focus for the team going forward, and our corporate supporters have continued to provide us with substantial backing.

Legacies

We have been very fortunate to have received legacy income during FY17 of £735,555 (£36,140 in FY16). Our policy is to view large legacy income as being outside ongoing income due to its typically one-off and unpredictable nature. Legacies are therefore invested as part of the core reserves to help ensure our long-term future.

Costs

Costs in FY17 were £737,508. Against continuing income (excluding the large, one off legacy of £675,000) of £501,886, this represents a shortfall of £(235,622).

Reserves

Our aim is to maintain reserves at a minimum of six months' worth of costs to ensure that the Society has a prudent level of resources to fund projects and to meet its financial responsibilities during periods of uncertain or fluctuating income streams.

Our level of reserves is currently significantly above this target. In FY17, unrestricted reserves stood at £1,244,141. As noted, the Board of Trustees continually reviews potential opportunities to invest for the good of the Society, whilst prudently managing reserves in an uncertain environment. We have identified several investments that will be made during FY18 for the benefit of the community.

Under the Memorandum and Articles of Association the trustees may invest surplus funds in any investment they consider appropriate. To this end we have invested in COIF Investment Funds, which invest based on a diversified and prudent investment strategy directly into assets to mitigate concentration of risk. As at the end of FY16 our funds had a market value of £567,558, with significant further investment made after year end from surplus cash balances.

The Haemophilia Society

Trustees' annual report

Year ended 31st March 2017

Key risks and uncertainties

Key risks to the charity fell into three distinct areas and were identified as:

Financial

Significant reliance on charitable contributions from members, corporates and other sources, and lack of certainty over the sustainability and security of these sources of funds.

Governance

Managing the risk of non-compliance with relevant legal and regulatory requirements.

Reputation

Managing reputational risk which could be impacted in any various ways: such as perceived failure to represent specific member(s) views on a particular issue; failure to successfully influence government or NHS decisions on key issues; failure to safeguard a vulnerable adult or child at one of The Society's events or services.

Each risk was carefully monitored and mitigation procedures put in place to reduce the likelihood and impact of the risk. The board of trustees reviewed the risks and mitigation quarterly.

Structure, governance and management

The Haemophilia Society is a registered charity in England (number 288260) and Scotland (number SCO39732) and company limited by guarantee (number 01763614). The Haemophilia Society's governing document is its Memorandum and Articles of Association.

The trustee board has

- seven ordinary trustees (elected by members of The Society)
- one honorary chairman
- up to four co-opted trustees

Elections take place prior to the AGM in November each year and trustees are elected for a three-year term. They may re-stand for election for a further three-year term and then must take at least one year's break. One further three-year term as a trustee is permitted, but having served nine years an individual may not stand for election or be co-opted to the board again.

A call for nominations is sent to every member in August requesting trustees nominations signed by another member. Information on the roles and responsibilities of a trustee and details of current trustees are available on our website.

The Chair is appointed to the board following an interview process.

The Haemophilia Society

Trustees' annual report

Year ended 31st March 2017

Statement of accounting and reporting responsibilities

The trustees (who are also the directors of The Haemophilia Society for the purposes of company law) are responsible for preparing the annual report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing these financial statements, the directors are required to:

- select the most suitable accounting policies and then to apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions, disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006 and the provisions of the charity's constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Relevant audit information

We, the directors of the company who held office at the date of approval of these financial statements as set out above each confirm, so far as we are aware, that:

- there is no relevant audit information of which the company's auditors are unaware; and
- we have taken all the steps that we ought to have taken as directors in order to make ourselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

In approving the trustees' annual report, we also approve the strategic report included therein, in our capacity as company directors.

On behalf of the board



Barry Flynn, Chair



Simon Mower, Treasurer

Date: 20 September 2017

The Haemophilia Society

Trustees' annual report

Year ended 31st March 2017

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF THE HAEMOPHILIA SOCIETY

We have audited the financial statements of The Haemophilia Society for the year ended 31 March 2017 on pages 19 to 23. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of the trustees and auditor

As explained more fully in the Statement of Accounting and Reporting Responsibilities set out on page 17, the trustees (who are also the directors of the company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view. Our responsibility is to audit and express an opinion on the financial statements in accordance with applicable law and International Standards on Auditing (UK and Ireland). Those standards require us to comply with the Auditing Practices Board's Ethical Standards for Auditors.

Scope of the audit of the financial statements

An audit involves obtaining evidence about the amounts and disclosures in the financial statements sufficient to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or error. This includes an assessment of: whether the accounting policies are appropriate to the company's circumstances and have been consistently applied and adequately disclosed; the reasonableness of significant accounting estimates made by the directors; and the overall presentation of the financial statements. In addition, we read all the financial and non-financial information in the Trustees' Annual Report to identify material inconsistencies with the audited financial statements and to identify any information that is apparently materially incorrect based on, or materially inconsistent with, the knowledge acquired by us in the course of performing the audit. If we become aware of any apparent material misstatements or inconsistencies we consider the implications for our report.

Opinion on financial statements

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 March 2017 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been properly prepared in accordance with the requirements of the Companies Act 2006.

Opinion on other matter prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit,

- the information given in the Trustees' Annual Report (including the Strategic Report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- The Trustees' Annual Report has been prepared in accordance with applicable legal requirements.

In light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Annual Report.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

Will Kennedy
John Howard (Senior Statutory Auditor)
for and on behalf of Wilkins Kennedy LLP
Statutory Auditor
Chartered Accountants
Bridge House
London Bridge
London, SE1 9QR

Date: 25 September 2017

The Haemophilia Society

Statement of financial activities (including income and expenditure account)

Year ended 31st March 2017

		2017			2016
		Unrestricted funds	Restricted funds	Endowment funds	Total
Note	£	£	£	£	£
Income and endowments from:					
Donations and legacies	2	858,599	176,302	-	1,034,901
Charitable activities	3	109,606	-	-	109,606
Investments	4	22,531	812	-	23,343
Other		9,036	-	-	9,036
Total income and endowments		999,772	177,114	-	1,176,886
Expenditure on:					
Raising funds	5	114,974	-	-	114,974
Charitable activities	6	426,582	195,952	-	622,534
Total expenditure		541,556	195,952	-	737,508
Net gains / (losses) on investments		40,762	-	-	40,762
Net income / (expenditure)	9	498,978	(18,838)	-	480,140
Transfers between funds		-	-	-	-
Net movement in funds		498,978	(18,838)	-	480,140
Reconciliation of funds:					
Total funds brought forward		804,458	36,742	19,344	860,544
Total funds carried forward		1,303,436	17,904	19,344	1,340,684

All income and expenditure derive from continuing activities.

The statement of financial activities includes all gains and losses recognised during the year.

The Haemophilia Society

Balance sheet

Year ended 31st March 2017

	Note	2017 £	2016 £
Fixed assets			
Tangible assets	12	19,245	27,881
Investments	13	567,558	524,558
		<hr/>	<hr/>
		586,803	552,439
Current assets			
Debtors	14	82,447	48,569
Cash at bank and in hand		766,919	339,172
		<hr/>	<hr/>
		849,366	387,741
Creditors: amounts falling due within one year	15	(95,485)	(79,636)
		<hr/>	<hr/>
Net current assets		753,881	308,105
		<hr/>	<hr/>
Net assets		1,340,684	860,544
Charity funds			
Endowment funds	16	19,344	19,344
Restricted funds	16	17,904	36,742
Unrestricted general funds	16	1,244,141	748,233
Local group funds	16	59,295	56,225
		<hr/>	<hr/>
Total charity funds	17	1,340,684	860,544

The financial statements were approved and authorised for issue by the board on 20 September 2017.

Signed on behalf of the board of trustees



Barry Flynn, Chair

The notes on pages 22 to 38 form part of these financial statements.

Company registration number: 01763614

The Haemophilia Society

Statement of cash flows

Year ended 31st March 2017

	Note	2017 £	2016 £
Net cash flow from operating activities	18	<u>411,561</u>	<u>(18,602)</u>
Cash flow from investing activities			
Payments to acquire tangible fixed assets		(7,157)	(1,219)
Receipts from sales of investments		-	175,000
Interest received		23,343	26,053
Net cash flow from investing activities		<u>16,186</u>	<u>199,834</u>
Net increase in cash and cash equivalents		427,747	181,232
Cash and cash equivalents at 1st April 2016		339,172	157,940
Cash and cash equivalents at 31st March 2017		<u>766,919</u>	<u>339,172</u>
Cash and cash equivalents consists of:			
Cash at bank and in hand		766,919	339,172
Cash and cash equivalents at 31st March 2017		<u>766,919</u>	<u>339,172</u>

The Haemophilia Society

Notes to the financial statements

Year ended 31st March 2017

1 Summary of significant accounting policies

(a) General information and basis of preparation

The Haemophilia Society is a company limited by guarantee in the United Kingdom. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity. The address of the registered office is given in the charity information on page 2 of these financial statements. The nature of the charity's operations and principal activities are to provide support and services to everybody affected by inherited bleeding disorders in the UK.

The charity constitutes a public benefit entity as defined by FRS 102. The financial statements have been prepared in accordance with *Accounting and Reporting by Charities: Statement of Recommended Practice* applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) issued on 16 July 2014, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Practice as it applies from 1 January 2016.

The financial statements are prepared on a going concern basis under the historical cost convention, with the exception of investments which are disclosed at fair value. The financial statements are prepared in sterling which is the functional currency of the charity.

The significant accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all years presented unless otherwise stated.

(b) Funds

Unrestricted general funds are available for use at the discretion of the trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

The Society is represented throughout the country by local groups. Local group funds are incorporated into The Society's financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds is charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

Endowment funds represent those assets which must be held permanently by the charity, principally the Philip Morris Art Award Fund and the Howard Abraham Memorial Award Fund. The interest earned on these funds is credited to the relevant restricted fund to fund awards.

(c) Income recognition

All incoming resources are included in the Statement of financial activities (SoFA) when the charity is legally entitled to the income after any performance conditions have been met, the amount can be measured reliably and it is probable that the income will be received.

The Haemophilia Society

Notes to the financial statements

Year ended 31st March 2017

1 Summary of significant accounting policies (continued)

Grant income is recognised in accordance with the terms of the grant and when the conditions of receipt have been complied with. When donors specify that grants given to the charity must be used in future accounting periods, the income is deferred until those periods.

Donations, legacies and similar incoming resources are included in the year in which they are receivable, which is when the charity becomes entitled to the resource.

Income from charitable activities includes income earned from community fundraising and events and local group activities to raise funds for the charity. Income is received in exchange for supplying goods and services in order to raise funds and is recognised when entitlement has occurred.

Investment income is earned through holding assets for investment purposes. It includes interest income, which is included when the amount can be measured reliably and the charity's right to receive payment is established.

No amount is included in the financial statements for volunteer time in line with the SORP (FRS 102).

(d) Expenditure recognition

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under the following headings:

- costs of raising funds includes fundraising salary and trading costs, direct and support costs;
- expenditure on charitable activities includes communications, membership, cultivation, services and advocacy and influencing costs; and
- other expenditure represents those items not falling into the categories above.

VAT is charged as an expense against the activity for which expenditure arose.

(e) Support costs allocation

Support costs are those that assist the work of the charity but do not directly represent charitable activities and include office overheads, governance costs, charity administration and salary core costs. They are incurred directly in support of expenditure on the objects of the charity and include project management carried out at headquarters. Where support costs cannot be directly attributed to particular headings they have been allocated to cost of raising funds and expenditure on charitable activities in proportion to direct costs incurred. Salary costs are allocated based on an analysis of staff time spent.

The analysis of these costs is included in note 7.

The Haemophilia Society

Notes to the financial statements

Year ended 31st March 2017

1 Summary of significant accounting policies (continued)

(f) Tangible fixed assets

Tangible fixed assets for use by the charity are stated at cost less accumulated depreciation.

Depreciation is provided on all tangible fixed assets, at rates calculated to write off the cost, less estimated residual value, of each asset on a systematic basis over its expected useful life as follows:

Office equipment and furniture	25% per annum, straight line
Leasehold property	Over life of lease
Leasehold improvements	Over life of lease

(g) Investments

Investments are recognised initially at fair value. Subsequent gains and losses, which represent the difference between the opening market value and closing market value or proceeds of sale, are recognised in the financial statements in the period to which they relate.

(h) Debtors and creditors receivable / payable within one year

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure.

(i) Impairment

Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the asset's cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit or loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

(j) Provisions

Provisions are recognised when the charity has an obligation at the balance sheet date as a result of a past event, it is probable that an outflow of economic benefits will be required in settlement and the amount can be reliably estimated.

(k) Leases

Rentals payable and receivable under operating leases are charged to the SoFA on a straight line basis over the period of the lease.

(l) Employee benefits

Pensions in respect of qualifying employees are provided by individual money purchase schemes. The Society's contributions to these schemes are charged to the SoFA in year in which they arise.

The Haemophilia Society

Notes to the financial statements

Year ended 31st March 2017

1 Summary of significant accounting policies (continued)

(m) Tax

The charity is an exempt charity within the meaning of schedule 3 of the Charities Act 2011 and is considered to pass the tests set out in Paragraph 1 Schedule 6 Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes.

(n) Going concern

The financial statements have been prepared on a going concern basis as the trustees believe that no material uncertainties exist. The trustees have considered the level of funds held and the expected level of income and expenditure for 12 months from authorising these financial statements. The budgeted income and expenditure is sufficient with the level of reserves for the charity to be able to continue as a going concern.

2 Income from donations and legacies

	2017 £	2016 £
Donations from individuals	93,905	92,097
Legacies	735,555	36,140
Corporate income	197,633	317,684
Trust income	7,740	5,350
Gift Aid	68	5,048
	<hr/> 1,034,901	<hr/> 456,319

Income from donations and legacies includes £176,302 (2016: £243,302) attributable to restricted funds, and £858,599 (2016: £213,017) attributable to unrestricted funds.

3 Income from charitable activities

	2017 £	2016 £
Local group activities	5,027	9,148
Community fundraising and events	104,579	148,410
	<hr/> 109,606	<hr/> 157,558

The Haemophilia Society

Notes to the financial statements

Year ended 31st March 2017

4 Income from investments

	2017 £	2016 £
Interest - fixed interest securities	21,194	24,031
Interest - deposits	2,149	2,022
	<u>23,343</u>	<u>26,053</u>

Income from investments includes £812 (2016: £nil) attributable to restricted funds, and £22,531 (2016: £26,053) attributable to unrestricted funds.

5 Analysis of expenditure on raising funds

	2017 £	2016 £
Direct costs	22,430	35,095
Support costs	92,544	97,315
	<u>114,974</u>	<u>132,410</u>

6 Analysis of expenditure on charitable activities

	Activities undertaken directly £	Grant funding of activities £	Support costs £	Total £
Communications	27,887	-	38,588	66,475
Membership	15,734	-	67,832	83,566
Services	136,011	-	245,989	382,000
Advocacy and influencing	40,774	-	47,749	88,523
Tanner Fund grants	-	1,970	-	1,970
	<u>220,406</u>	<u>1,970</u>	<u>400,158</u>	<u>622,534</u>

£195,952 (2016: £268,763) of the above costs were attributable to restricted funds. £426,582 (2016: £252,323) of the above costs were attributable to unrestricted funds.

The Haemophilia Society

Notes to the financial statements

Year ended 31st March 2017

7 Allocation of support costs

Support cost	Basis of allocation	Raising funds	Charitable activities	Total
	£	£	£	£
Governance	% of direct costs	2,088	20,697	22,785
Travel, postage and carriage	% of direct costs	1,429	4,181	5,610
Information technology	% of direct costs	1,506	14,933	16,439
Salary costs	% of staff time	75,752	243,485	319,237
Depreciation	% of direct costs	1,447	14,346	15,793
Office costs (incl. rental)	% of direct costs	4,527	44,886	49,413
Recruitment, training and temp staff	% of direct costs	3,993	39,768	43,761
Other expenses	% of direct costs	1,802	17,862	19,664
Total		92,544	400,158	492,702

8 Governance costs

	2017 £	2016 £
Trustee expenses	5,415	7,964
Auditors' remuneration – current year	6,250	6,250
Auditors' remuneration – prior year	1,250	5,178
Other expenses	9,870	10,335
	<u>22,785</u>	<u>29,727</u>

9 Net income / (expenditure) for the year

Net income / (expenditure) is stated after charging:

	2017 £	2016 £
Depreciation of tangible fixed assets	15,793	14,004
Operating lease rentals	29,216	36,725
Auditors' remuneration	6,250	6,250
	<u></u>	<u></u>

The Haemophilia Society

Notes to the financial statements

Year ended 31st March 2017

10 Trustees' and key management personnel remuneration and expenses

The trustees neither received nor waived any remuneration during the year (2016: £Nil).

The Charity considers its key management personnel to be the board of trustees and the Chief Executive, Liz Carroll. The aggregate benefits of key management personnel amounted to £75,717 (2016: £71,438).

The reimbursement of trustees' expenses was as follows:

	2017 Number	2016 Number	2017 £	2016 £
Travel, subsistence and accommodation	5	7	1,760	2,529

11 Staff costs and employee benefits

The average monthly number of full-time equivalent employees during the year was as follows:

2017 Number	2016 Number
10	7

The total staff costs and employee benefits was as follows:

	2017 £	2016 £
Wages and salaries	270,840	220,033
Social security	25,292	22,417
Defined contribution pension costs	23,105	2,579
Interim staff	10,773	13,268
Recruitment and training	32,988	4,476
	<u>362,998</u>	<u>262,773</u>

One employee received emoluments of more than £60,000 during the year ended 31st March 2017 (2016: one) and within the following bands:

	2017	2016
£70,001 - £80,000	<u>1</u>	<u>1</u>

The Haemophilia Society

Notes to the financial statements

Year ended 31st March 2017

12 Tangible fixed assets

	Computers and Office Equipment £
Cost:	
At 1st April 2016	56,016
Additions	7,157
At 31st March 2017	<u>63,173</u>
Depreciation:	
At 1st April 2016	28,135
Charge for the year	15,793
At 31st March 2017	<u>43,928</u>
Net book value:	
At 31st March 2017	<u>19,245</u>
At 31st March 2016	<u>27,881</u>

13 Fixed asset investments

	COIF Investment £	Other investments £	Total £
Cost or valuation			
At 1st April 2016	523,609	949	524,558
Revaluation	43,000	-	43,000
At 31st March 2017	<u>566,609</u>	<u>949</u>	<u>567,558</u>

14 Debtors

	2017 £	2016 £
Prepayments and accrued income	20,281	26,403
Other debtors	62,166	22,166
	<u>82,447</u>	<u>48,569</u>

The Haemophilia Society

Notes to the financial statements

Year ended 31st March 2017

15 Creditors: amounts falling due within one year

	2017 £	2016 £
Trade creditors	22,904	56,400
Accruals and deferred income	55,417	13,645
Other creditors	17,164	9,591
	<u>95,485</u>	<u>79,636</u>

16 Fund reconciliation

Unrestricted funds

	Balance at 1st April 2016 £	Income £	Expenditure £	Gains / (losses) £	Balance at 31st March 2017 £
Local Groups	56,225	5,027	(1,957)	-	59,295
General Funds	748,233	994,745	(539,599)	40,762	1,244,141
	<u>804,458</u>	<u>999,772</u>	<u>(541,556)</u>	<u>40,762</u>	<u>1,303,436</u>

Restricted funds

	Balance at 1st April 2016 £	Income £	Expenditure £	Balance at 31st March 2017 £
Talking Red	20,000	7,500	(27,500)	-
Tanner Fund	3,960	-	-	3,960
Memorial Service	12,782	-	-	12,782
Local Group Forum Event	-	6,000	(6,000)	-
Youth Activity & Teen Weekends	-	57,964	(57,964)	-
Ageing	-	15,000	(15,000)	-
Inhibitors	-	5,000	(5,000)	-
Newly Diagnosed	-	31,000	(31,000)	-
AGM	-	24,500	(24,500)	-
Ambassadors	-	28,988	(28,988)	-
Philip Morris Art Award	-	560	-	560
Howard Abrahams Memorial Award	-	602	-	602
	<u>36,742</u>	<u>177,114</u>	<u>(195,952)</u>	<u>17,904</u>
Endowment Funds				
Philip Morris Art Award	13,344	-	-	13,344
Howard Abrahams Memorial Award	6,000	-	-	6,000
	<u>56,086</u>	<u>177,114</u>	<u>(195,952)</u>	<u>37,248</u>

The Haemophilia Society

Notes to the financial statements

Year ended 31st March 2017

16 Fund reconciliation (continued)

Fund descriptions

a) Unrestricted funds

The Society is represented throughout the country by local groups. Group funds are incorporated into the Society's financial statements.

b) Restricted funds

Talking Red: Talking Red includes all our work for women with bleeding disorders including an awareness campaign and services for those with a diagnosis.

Tanner Fund: A hardship fund providing grants of up to £200.

Memorial Service: Funds held for the administration of an annual service of thanksgiving and remembrance in London for those who died as a result of contamination of blood products in the 1970s and 1980s.

Local Group Forum Event: Funding to provide a training and development event for members of our local groups.

Youth Activity and Teen Weekends: Funds to support services for young people and teenagers with a bleeding disorder.

Ageing: Fund to support our services and events for our ageing community.

Inhibitors: Fund to support our services and events for people with an inhibitor.

Newly diagnosed: Fund to support our services and events for families with a newly diagnosed child with a bleeding disorder.

AGM: Funding for The Annual General meeting and Conference of The Society.

Ambassadors: Fund to support six youth ambassadors, who are volunteer advocates for the charity, to receive training, attend events and services and support the development of the society's work and strategy.

c) Endowment funds

Philip Morris Art Award: This award is open to students with haemophilia or related bleeding disorders studying the arts. Preference will be given to a student studying music, as a reflection of Philip's love of music developed in later life.

Howard Abrahams Memorial Award: This is a bursary awarded to an individual with haemophilia or related bleeding disorders in pursuit of one of the professions or study relating to a profession. This award has been made possible by the Abrahams family in memory of their son.

Donations and interest earned on these funds are credited to the relevant restricted fund.

The Haemophilia Society

Notes to the financial statements

Year ended 31st March 2017

17 Analysis of net assets between funds

	Unrestricted funds	Local group funds	Restricted funds	Endowment funds	Total
	£	£	£	£	£
Fixed assets	567,459	-	-	19,344	586,803
Net current assets	676,682	59,295	17,904	-	753,881
Total	1,244,141	59,295	17,904	19,344	1,340,684

18 Reconciliation of net income / (expenditure) to net cash flow from operating activities

	2017 £	2016 £
Net income / (expenditure) for year	480,140	(25,815)
Interest receivable	(23,343)	(26,053)
Depreciation of tangible fixed assets	15,793	14,004
(Gains) / losses on investments	(43,000)	17,658
Increase in debtors	(33,878)	(15,064)
Increase in creditors	15,849	16,668
Net cash flow from operating activities	411,561	(18,602)

19 Pensions and other post-retirement benefits

The charity operates a defined contribution pension plan for its employees. The amount recognised as an expense in the period was £23,105 (2016: £2,579).

20 Financial commitments

The total of future minimum lease payments under non-cancellable operating leases for each of the following periods are:

	2017 Within 1 year £	2017 Within 1-5 years £	2016 Within 1 year £	2016 Within 1-5 years £
Land and buildings	28,665	4,500	28,665	33,165
Other	1,868	1,401	1,868	3,269
	30,533	5,901	30,533	36,434

The Haemophilia Society

Notes to the financial statements

Year ended 31st March 2017

21 Related party transactions

There are no related party transactions during the period (2016: £ nil).

